The Latest Breaking News from AbbVie

North Chicago-based drugmaker AbbVie must pay back Medicare for raising the price of its blockbuster drug Humira too quickly, the federal government said Wednesday.

A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?

AbbVie stock won at least one upgrade Friday after issuing long-awaited guidance for Humira for the first year it faces new competition.

AbbVie stock inched higher Thursday after the company reported mixed earnings and issued a light profit outlook.

The Dow Jones rallied 250 points Thursday after weekly first-time jobless claims. Disney shares surged on earnings results.

The Fed will likely keep raising interest rates to bring inflation down to its desired level. This is expected to keep the stock market and the economy under pressure this year. Amid the uncertainty, investors looking for passive income could add fundamentally strong dividend-paying stocks AbbVie (ABBV), Valero Energy (VLO),…

Making money in an up market is easy. But showering investors with gains when stocks fall is far more challenging for the best mutual funds.

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.

NHS crisis, withdrawal of tax credits and exit from EU blamed for fall in UK share of R&D market

While the stock market and the economy have been subdued by progressive interest-rate increases, AbbVie Inc. (ABBV) has not only reported a robust third quarter but also demonstrated its confidence in its long-term prospects by raising its quarterly dividend. Read on….